- Home
- CRIS vs BLRX Comparison
CRIS vs BLRX Comparison
Compare CRIS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | BLRX |
|---|---|---|
| Founded | 2000 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0M | 12.6M |
| IPO Year | 2000 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CRIS | BLRX |
|---|---|---|
| Price | $0.50 | $3.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $17.00 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 255.2K | 37.3K |
| Earning Date | 05-07-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,898,000.00 | N/A |
| Revenue This Year | $27.10 | N/A |
| Revenue Next Year | $67.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.46 | $2.15 |
| 52 Week High | $3.13 | $7.77 |
Technical Indicators
Market Signals| Indicator | CRIS | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 56.05 |
| Support Level | $0.49 | $2.66 |
| Resistance Level | $0.63 | $3.11 |
| Average True Range (ATR) | 0.04 | 0.21 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 24.80 | 51.85 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.